If it's the right drug it will make deals before it even sees humans A LOT of huge figure deals on pre-clinical drugs or potential ones.
2016 alone and not even touching into 2017 deals
> AbbVie payed $685M on pre-clinical deal with Argenx last year
> Amicus payed MiaMed $90M pre-clinical
>Celgene stitched $2.6B deal with Jounce pre-clinical
> Janssen put up $700M for Macrogenix pre-clinical
Ann: PAT-DX1 Conjugated to Nanoparticles, Targets Tumors, page-61
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 2053666 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 3325244 | 5 |
View Market Depth
| Last trade - 16.12pm 19/08/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable